A detailed history of Bank Of America Corp transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 99,915 shares of FULC stock, worth $298,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,915
Previous 69,886 42.97%
Holding current value
$298,745
Previous $433,000 17.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $95,492 - $292,482
30,029 Added 42.97%
99,915 $356,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $49,233 - $76,649
8,233 Added 13.35%
69,886 $433,000
Q1 2024

May 15, 2024

SELL
$6.7 - $12.0 $842,987 - $1.51 Million
-125,819 Reduced 67.11%
61,653 $582,000
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $175,644 - $378,905
55,234 Added 41.77%
187,472 $1.27 Million
Q2 2023

Aug 14, 2023

BUY
$2.26 - $3.8 $203,101 - $341,498
89,868 Added 212.1%
132,238 $436,000
Q1 2023

May 12, 2023

SELL
$2.83 - $13.99 $43,194 - $213,529
-15,263 Reduced 26.48%
42,370 $120,000
Q4 2022

Feb 10, 2023

BUY
$5.01 - $8.35 $139,353 - $232,255
27,815 Added 93.28%
57,633 $419,000
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $363,337 - $672,025
-73,849 Reduced 71.24%
29,818 $242,000
Q2 2022

Aug 12, 2022

BUY
$4.2 - $24.0 $373,111 - $2.13 Million
88,836 Added 598.99%
103,667 $507,000
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $130,804 - $310,595
-13,133 Reduced 46.96%
14,831 $351,000
Q4 2021

Feb 08, 2022

BUY
$14.0 - $28.44 $286,944 - $582,906
20,496 Added 274.45%
27,964 $495,000
Q3 2021

Nov 15, 2021

SELL
$7.28 - $30.97 $20,449 - $86,994
-2,809 Reduced 27.33%
7,468 $211,000
Q2 2021

Sep 13, 2021

BUY
$8.09 - $12.0 $83,140 - $123,324
10,277 New
10,277 $108,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $156M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.